|
| General Information |
| Business: |
We are a biopharmaceutical company established in 1995 focused on developing products for the treatment of cancer and infectious diseases based on our proprietary Tarmogen® platform. Tarmogens activate the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells, in contrast to traditional vaccines which predominately stimulate antibody production. We believe that our Tarmogen platform has applicability to a number of diseases, and may enable us to develop a broad portfolio of products. We have four Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
25 |
Founded: |
1995 |
|
| Contact Information |
| Address: |
1450 Infinite Drive, Louisville, CO 80027, US |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 21.5 mil (last 12 months) |
|
| Net Income: |
$ -4.5 mil (last 12 months) |
|
| IPO Profile |
|
|
|
|
